Exodus Point Capital Management, LP Phathom Pharmaceuticals, Inc. Transaction History
Exodus Point Capital Management, LP
- $11.4 Billion
- Q2 2025
A detailed history of Exodus Point Capital Management, LP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 15,146 shares of PHAT stock, worth $163,273. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,146
Previous 79,311
80.9%
Holding current value
$163,273
Previous $497,000
70.82%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PHAT
# of Institutions
138Shares Held
60.5MCall Options Held
1.35MPut Options Held
1.19M-
Frazier Life Sciences Management, L.P. Menlo Park, CA12.5MShares$134 Million6.31% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$80.5 Million20.28% of portfolio
-
Invesco Ltd. Atlanta, GA4.14MShares$44.6 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$37.7 Million41.56% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$31.5 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $422M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...